Oz: Trump Administration Weighing ACA Subsidies Extension

Dr. Mehmet Oz, the administrator for the Centers for Medicare and Medicaid Services (CMS), said Sunday the Trump administration is holding “discussions” on extending subsidies offered under the Affordable Care Act (ACA). “There are discussions around extending the subsidies, if we deal with the fraud, waste and abuse that, right now, is paralyzing the system,” Oz told ...

Read More

A Record Number Of Americans Are Anxious About Health Care Costs Going Into Next Year

Almost half of adults, 47%, say they’re worried they won’t be able to afford health care next year — the highest level since West Health and Gallup began tracking in 2021.

Read More

Prescription Drug Costs Remain A Top Concern For Americans Amidst Policy Proposals

With enhanced Affordable Care Act premium subsidies set to expire at the end of this year, health care affordability was a contentious issue in the recent government shutdown. Both political parties are making policy proposals aimed at lowering prescription drug costs for American families. The Trump administration recently announced several actions addressing the cost of ...

Read More

Senate Republican Pitches Swapping Enhanced ACA Tax Credits With Health Savings Accounts

Sen. Bill Cassidy on Monday proposed replacing enhanced Affordable Care Act premium tax credits with pre-paid health savings accounts. The Louisiana Republican’s proposal comes as lawmakers scramble to find a remedy for skyrocketing costs of Obamacare health insurance premiums. The boosted ACA tax credits, which this year have lowered the cost of Obamacare plans for about 20 million Americans, are set to expire at the end ...

Read More

Trump’s Broadside Against Health Insurers Is A Cautionary Tale For Industry

Insurers and drug companies facing dire threats to their bottom lines this year from President Donald Trump and Republicans in Congress had to make a choice: Stand and fight, or go to ground and cut some deals. Insurers fought in a bid to kill the threat; drugmakers cut deals to mitigate the damage. The early ...

Read More

FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say. These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square